<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02426164</url>
  </required_header>
  <id_info>
    <org_study_id>633913</org_study_id>
    <nct_id>NCT02426164</nct_id>
  </id_info>
  <brief_title>Liposomal Bupivacaine in Total Knee Arthroplasty</brief_title>
  <official_title>Analgesic Efficacy of Liposomal Bupivacaine in Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Miller Orthopedic Specialists</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Creighton University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CHI Health Mercy Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Miller Orthopedic Specialists</source>
  <brief_summary>
    <textblock>
      Liposomal bupivacaine is a novel local anesthetic designed for prolonged pain relief. Despite
      its long-acting analgesic potential, liposomal bupivacaine is significantly more expensive
      than other local anesthetic alternatives. The primary aim of this investigation is to examine
      whether or not liposomal bupivacaine provides superior pain relief or clinically significant
      opioid-sparing effects versus a control to justify its cost.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Could not receive facility approval
  </why_stopped>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean visual analog scale (VAS) pain scores</measure>
    <time_frame>Night of surgery</time_frame>
    <description>Self-reported pain scores from 0=no pain to 10=severe pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean visual analog scale (VAS) pain scores</measure>
    <time_frame>Post-operative day 1</time_frame>
    <description>Self-reported pain scores from 0=no pain to 10=severe pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean visual analog scale (VAS) pain scores</measure>
    <time_frame>Post-operative day 2</time_frame>
    <description>Self-reported pain scores from 0=no pain to 10=severe pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain assessment phone call</measure>
    <time_frame>Post-operative day 3</time_frame>
    <description>Subjects will be called on post-operative day three by one of the investigators of the study. Subjects will be asked to rate their current pain level from 1 to 10 and to rate their worst pain level from 1 to 10 that day.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>Complications will be followed for the duration of patients' hospital stay, an expected average of 2-3 days.</time_frame>
    <description>Number of patients with complications</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Pain, Postoperative</condition>
  <condition>Arthroplasty, Replacement, Knee</condition>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Liposomal bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Periarticular infiltration of 20cc of liposomal bupivacaine with 20cc of normal saline administered prior to cementation of knee implants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bupivacaine HCl, morphine, epinephrine, methylprednisolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Periarticular infiltration of 24c of bupivacaine HCl, 0.8cc morphine, 0.3cc epinephrine, and 1cc of methylprednisolone administered prior to cementation of knee implants</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal bupivacaine</intervention_name>
    <description>Periarticular infiltration of the liposomal bupivacaine with 20cc of normal saline</description>
    <arm_group_label>Liposomal bupivacaine</arm_group_label>
    <other_name>Exparel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupivacaine HCl, morphine, epinephrine, methylprednisolone</intervention_name>
    <description>Periarticular infiltration of 24c of bupivacaine HCl, 0.8cc morphine, 0.3cc epinephrine, and 1cc of methylprednisolone</description>
    <arm_group_label>bupivacaine HCl, morphine, epinephrine, methylprednisolone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing a primary unilateral total knee arthroplasty by the PI of the
             trial

        Exclusion Criteria:

          -  Patients with a sensitivity to marcaine

          -  Pregnant or lactating women

          -  Non-English speaking individuals
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clifford K Boese, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Miller Orthopedic Specialists</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Miller Orthopedic Specialists</name>
      <address>
        <city>Council Bluffs</city>
        <state>Iowa</state>
        <zip>51503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2015</study_first_submitted>
  <study_first_submitted_qc>April 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2015</study_first_posted>
  <last_update_submitted>March 18, 2016</last_update_submitted>
  <last_update_submitted_qc>March 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

